{"name":"Shield Therapeutics","slug":"shield-therapeutics","ticker":"","exchange":"","domain":"","description":"Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of innovative treatments for patients with iron deficiency and other gastrointestinal disorders. The company has a portfolio of four drugs, including marketed and phase 3 candidates, aiming to address significant unmet medical needs.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQRVQ2bF9WRGhPLXh5T1dwOW1vVU5NQTgwTEFZamRwdUJzSHNrMDh3T0NibzAyNHFNRk1jUjlod2ZvUEk4SEIwLWJmVzNHdnBydURHWmJ6MDlwbWNLOEtHdnBwVkdCb2VOcjJYWlRuSEVNc1hlTFpHc3dhYXoxY1hNTFdtUndSQzdKN05XRTBxUEdqZHY5Y1BCNnF3ZXlYd0VoNHZpbFN3NDI3YXAx?oc=5","date":"2026-03-03","type":"pipeline","source":"Sharecast.com","summary":"Shield's Accrufer MA application accepted in China - Sharecast.com","headline":"Shield's Accrufer MA application accepted in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPNWYzaWhSc1g0NDA3WFpYWmlPMUdfUE1lcEZsRzhqNEZJTnozbUpxRG1KS25EUThzZ3puUXB3VFFZN0IwQzZlcjhIQmo2bDh4N19CM09XLXZPeVVyNm1rX1V6V0VPNWpQUFZjMnc3bC1XTEFTX0plbG9MWmo4dG9yTTZvQjV0VHBGZXhOZ3Blam9pX0J2b0VHcFRXc09SVTV5SWRUcXFaNDJkNU9lNzVaM2t2WHcwVGRYZFJ2YkZMRElTbTY4d0Mw?oc=5","date":"2026-02-09","type":"pipeline","source":"Kalkine Media","summary":"Shield Therapeutics plc Strengthens Market Position as FTSE100 Healthcare Innovator - Kalkine Media","headline":"Shield Therapeutics plc Strengthens Market Position as FTSE100 Healthcare Innovator","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOdVVsNFRHMWFYRkJ5azVfQmNZZVVaRDJjMFByeUhMMEdZWi1sMjNua3FDaW91T01jd1ZBN0VvMkNjMm5ZanJDc3FUcjRoTXB1blVnTHhQSUlBZXRsSDZpQXdUUENnWjZXQ19OOWpPVExpSjNZakRBbXJjZVNnVTBqX0tRb3FKSFNBNy05ZWMzOW1iQUpzWFNjUUV4QVcxeDQyZ0xxR1I2MTVHMW5URVQ3Yk9vUzQwYklIc3c?oc=5","date":"2026-01-30","type":"regulatory","source":"Kalkine Media","summary":"Shield Therapeutics on FTSE Index Market Landscape With Regulatory Update - Kalkine Media","headline":"Shield Therapeutics on FTSE Index Market Landscape With Regulatory Update","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-15","type":"pipeline","source":"simplywall.st","summary":"Analysts Expect Breakeven For Shield Therapeutics plc (LON:STX) Before Long - simplywall.st","headline":"Analysts Expect Breakeven For Shield Therapeutics plc (LON:STX) Before Long","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNaW1ydEQyR09UUEVoWm5qVGZmNlZzYlI5U3BObGVXcnRjRGlYRUxEYUJ3MmJXdnViN2VHYk1zRkNUVWRfdGlONFhSSHA4QndUVlpWdDQ2aDRNMHhyMWdGYThscHdRM1VDbnV0N0NHQjZlTlpWbk1GMmNrZWZFcno3a2tNYWVSZ0NYYzFub3M0ZjgxSFZRaHRCOEZRRk1paGN2RWZyWVEyYW5OTDA?oc=5","date":"2026-01-12","type":"deal","source":"Fool UK","summary":"Shield Therapeutics’ share price is up 318% in 1 year! Should I buy now? - Fool UK","headline":"Shield Therapeutics’ share price is up 318% in 1 year! Should I buy now?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNXzRESDVnWFAtb2Y4WUI0WkRydU40WDBUbVpFNFViUXpqVS1XMGRLSG5BTWVlaGdYSlhWbjRNd2NSUDl6WjdBMkdob3ZjZE5HSEwtQzRLeW5xR2J4b0pIcmp5Tm4xeEVaVksxeEcwSGpXaEF2enZ3ZmY4aWszNTlGRnQtOA?oc=5","date":"2025-12-22","type":"pipeline","source":"Yahoo Finance","summary":"When Will Shield Therapeutics plc (LON:STX) Breakeven? - Yahoo Finance","headline":"When Will Shield Therapeutics plc (LON:STX) Breakeven?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-25","type":"pipeline","source":"simplywall.st","summary":"Shield Therapeutics plc's (LON:STX) Subdued P/S Might Signal An Opportunity - simplywall.st","headline":"Shield Therapeutics plc's (LON:STX) Subdued P/S Might Signal An Opportunity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPS1E2VGY5S2owcmlYbDI5RWZVbU43WXNLUUM0SW00eTRXakZydGpVWVpFTzdVOVM4LUNpbVpuNHltTDZzREt1ZllIOE5LN3ZHanFua3pyemlPaHlzOEMtNU41YlVWZnBWemlvZXlYeUNsUkxuNzhnT2d4RHFwMzIxTjFhdUV1YXk1UDFETm1Hamg2X09ORVF6WE5QcUhYSjQ?oc=5","date":"2025-10-23","type":"pipeline","source":"business-live.co.uk","summary":"Shield Therapeutics signals strong momentum as iron deficiency drug sales ramp up - business-live.co.uk","headline":"Shield Therapeutics signals strong momentum as iron deficiency drug sales ramp up - business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPOWJzbzFDa0lleUxWVndtTFhBUUk4V3ROeWFGZUtNT3NuTU55NjYyS2hDZlFIWXN6bWttY3lSRXN0X1RuOGQ4NExoemdweGlGWXRJQ3dBTGVHeUhoN252Uk9zajBUd0Q3NWJOSjdsWWZWVnFuSUhoa1lxU2JBM3V5S1lmbzBsODU4emU1b2t2dw?oc=5","date":"2025-08-22","type":"earnings","source":"business-live.co.uk","summary":"Revenues rise and losses narrow as Shield Therapeutics as US sales deliver major boost - business-live.co.uk","headline":"Revenues rise and losses narrow as Shield Therapeutics as US sales deliver major boost - business","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQVmg1T3VrS3l3dGRzbWlnVmNXb2VHVW13VnlUQUxhQVpqRjRtd0RCN0ZDN1hodWpDUkFxcmx6VVctYnA4LWRHZm9BY3dzNlJWYWRuMnZlb054aDFKYVhhb1pva2ZCY1ZvdEt1ejl3T2t1clhJOEdBNUhCZFh2cFRzX1h2cU5TRW5vMG1VOQ?oc=5","date":"2025-04-26","type":"earnings","source":"Yahoo Finance","summary":"Shield Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance","headline":"Shield Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxQbXFFdWJCdFdSd2lpSEtkYUtvdWYyMTJ0Qng4LVJ5aVFTMlJmb3pKNGxNajBhY1FGSEhCYkxrRWpKVk9US1NVb3dXaWs5Vk9XRUtsVDhhU21ReHZzWHRkQnhtR25iR3ZLT3VFc0ROYi1ZOWVjM01xbnN1MDVwR1RnY0o4eUozMUJBNDNDMUhnX0l0aDh3bzZsVjkzNHMzR2U2d2ZMbHkxM3BrbmJRMkJLbXlkOUhFZThEV3RHTEtuSXN5TWNWczk4UVRhODlqNlBfSFNsQjk0MGdCcnBvLS02U0dn?oc=5","date":"2023-05-04","type":"pipeline","source":"Slaughter and May","summary":"AOP on takeover offer for Shield Therapeutics plc - Slaughter and May","headline":"AOP on takeover offer for Shield Therapeutics plc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxPeXdSeVhXc1JjcjY1Ry1KZHR6TEkxM0xTN2JsUW00NW1IUHdfVFJzTUpBZXlxYzI4NHkzN3h5dnpIR25na3h6aHcya3l5dkxDYzdtb1F5WWJWYTI1S2NBQUc4US1vTGl3ZXNvUVVGWHJhRG1LSERtb3RIOHpuY0kyZS1HR3gtcUUyY24xeTZMMHN5VDJ0ZjM5MmtYYWtTeDdzMG1Qd0xSWWNDdy1TckNhSl9MVHItU2xIREZreXVHMXl1UHlmVW54djdFRlBmZGFSa1R1em5YVC16YlJrNFVZR2V5TGZhanhnUFd3Zkxn?oc=5","date":"2022-01-05","type":"pipeline","source":"Proactive financial news","summary":"Shield Therapeutics signs Canada licence agreement for Accrufer with KYE Pharmaceuticals - Proactive financial news","headline":"Shield Therapeutics signs Canada licence agreement for Accrufer with KYE Pharmaceuticals","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}